Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the 12 months ended December 31, 2024, and provides updates on its antiviral product pipeline, ...

Researchers have identified antibodies that could lead to a broadly protective norovirus vaccine and new treatment options.

Norovirus infects over 700 million people each ... targets a previously unknown weak spot in the virus's structure. Unlike typical antibodies that attack only one or two strains, VX22 neutralizes ...

Norovirus infects over 700 million people each ... targets a previously unknown weak spot in the virus's structure. Unlike typical antibodies that attack only one or two strains, VX22 neutralizes ...

Norovirus infects over 700 million people each year ... One of the most promising antibodies identified, VX22, targets a previously unknown weak spot in the virus’s structure. Unlike typical ...

Q4 2024 Earnings Call Transcript March 20, 2025 Vaxart, Inc. beats earnings expectations. Reported EPS is $-0.05, ...

The second publication in science translational medicine focused on identifying broadly neutralizing antibodies targeting the human norovirus and to determine the biochemical and structure basis ...

The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing ...